


# Aminoglycoside Guideline Pediatrics UCSF


How To Use These Guidelines



CONTRIBUTORS

*This document was developed by the Pediatric  
Antimicrobial Stewardship Program [peds.asp@ucsf.edu](mailto:peds.asp@ucsf.edu)  
(Last Updated: 09/2025)*

REFERENCES




# HOW TO USE THESE GUIDELINES

These guidelines serve as a reference for clinical pharmacists at UCSF caring for pediatric patients receiving aminoglycosides (amikacin, gentamicin, and tobramycin).

The document is designed to be interactive, with hyperlinks for quick navigation between sections. Each section links back to the main page, though the guidelines may also be read straight through as a PDF. If text appears small, adjust the view by zooming in (Ctrl + mouse wheel or the “+” button in the PDF toolbar).

## **Disclaimer**

These guidelines are intended to support, not replace, clinical judgment. Always verify your work carefully. Pharmacokinetic principles should be applied in patients for empiric dosing and when calculating regimens based on aminoglycoside levels.





# Why Bayesian Modeling?

◆ Why We're Using Bayesian Modeling for Most Patient Groups (Infants, children, adolescents, and special populations — **neonates remain on the UCSF Aminoglycoside Dosing Calculator for now**)

- Ease of use: Faster, simpler data entry
- Better documentation: Provides a complete record of each patient's pharmacokinetics.
- More consistent care: Standardizes approach across pharmacists, reducing variability.
- Flexibility: Accurately accounts for missed doses, dose changes, and renal fluctuations.
- Future-proof: Aligns with best practices in therapeutic drug monitoring (TDM).

# SELECT THE PEDIATRIC POPULATION YOU ARE TREATING



[RETURN TO MAIN PAGE](#)





**Determine the initial dose using the Gentamicin/Tobramycin ICN Dosing Card**



**Determine the goal peak and trough**

| Gentamicin/Tobramycin    |                        |                          |
|--------------------------|------------------------|--------------------------|
|                          | Goal Extrapolated Peak | Goal Extrapolated Trough |
| Gram-negative infections | 8 to 12 mcg/mL         | < 0.5 mcg/mL             |



**Obtain serum concentrations**

Patients on therapy for 48-hour rule out or with expected duration of therapy < 5 days **do not** routinely need therapeutic drug monitoring (TDM).

Situations where TDM is typically indicated:

- Expected duration of treatment is  $\geq 5$  days
- 24-hour urine output (UOP) is < 2 mLs/kg/hour
- A pathogen is identified (this helps ensure extrapolated peak is minimum of 8 to 10X MIC)

**If a pathogen is identified, peak and trough monitoring is recommended. If blood volume is an issue, may need to limit to troughs only on a case-by-case basis**

Timing of TDM: Obtain a trough level 30 minutes prior to dose. Obtain a peak level 30 minutes after end of infusion.

- q24h & q36h – prior to 3rd dose
- q48h – prior to 2nd dose

**If a pathogen is NOT identified, consider trough-based monitoring without peaks to ensure drug clearance.**



**Dose Adjustments**

Use our [UCSF Aminoglycoside Dosing Calculator](#) to calculate an extrapolated peak and an extrapolated trough. Model a new aminoglycoside regimen as clinically indicated and recommend a new dosing regimen as needed.

Please refer to the [Aminoglycoside Calculator Guide](#) for further instructions on how to use.



**Continued Monitoring**

Clinical pharmacist will obtain serum concentrations as described in step 3 once to twice weekly to verify appropriateness of dosing and make recommendations as needed.

More frequent serum concentrations are indicated in patients with changing clinical status, changing renal status, or concern for toxicity.




**Documentation**

Please write a pharmacokinetic progress note in the patient's chart regardless of whether a dose adjustment was required or not.

[Dotphrase](#) = .RXAMINOGLYCOSIDEPEDS

RETURN TO MAIN PAGE





## Determine the initial dose

|            | Usual Dose   | Dose Adjustment   |
|------------|--|---|
| Gentamicin | Treatment: 7 mg/kg/dose IV q24h<br>Synergy: 3 mg/kg/dose IV q24h | Adjust for CrCl < 50 ml/min/1.73m2*<br><br>*Consider ASP/ID pharmacist consult for dose adjustment/level assessment |
| Tobramycin | Treatment: 7 mg/kg/dose IV q24h                                  |   |



## Determine the goal peak and trough

| Gentamycin/Tobramycin                   |                        |                          |
|---|------------------------|--------------------------|
|   | Goal Extrapolated Peak | Goal Extrapolated Trough |
| Gram-negative infections                | 15 to 30 mcg/mL        | < 1 mcg/mL               |
| Gram-positive synergy (gentamicin only) | NA                     | < 1 mcg/mL               |



## Obtain serum concentrations

Patients on therapy for 48-hour rule out or with expected duration of therapy < 5 days **do not** routinely need therapeutic drug monitoring (TDM).  
For synergy: obtain trough 2 to 4 days into therapy to ensure clearance

### Situations where TDM is indicated:

- Expected duration of treatment is  $\geq 5$  days
- CrCl < 50 ml/min/1.73m2
- Rapidly declining renal function
  - SCr > 50% increase from baseline **OR**
  - 24-hour urine output (UOP) is < 2 mLs/kg/hour (if available for younger patients)

### If TDM is indicated:

| Renal Function  | When to obtain level  | After which dose? |
|---|---|-------------------|
| CrCl > 50<br>or<br>CRRT                                   | Post dose levels 2 and 6 hours after end of infusion                              | 1st or 2nd dose   |
| CrCl < 50   | Post dose levels 2 and 12 hours after end of infusion                             | 1st or 2nd dose   |
| Intermittent hemodialysis (iHD), peritoneal dialysis (PD) | Level obtained prior to the hemodialysis treatment is recommended to guide dosing | 1st dose          |



## Dosing Adjustments

Use Bayesian software to estimate extrapolated peak and trough concentrations. Apply Bayesian modeling to evaluate the current regimen and adjust therapy as clinically indicated.

For step-by-step instructions on how to perform Bayesian modeling, please refer to the [Aminoglycoside PrecisePK Job Aid](#).



## Continued Monitoring

- Check serum concentrations weekly to confirm appropriate dosing.
- Monitor more often if clinical status, renal function, or toxicity risk changes.
- For synergy, obtain an initial trough and utilize weekly troughs thereafter to ensure clearance.



## Documentation

Please write a pharmacokinetic progress note in the patient's chart regardless of whether a dose adjustment was required or not.

Dotphrase = .RXAMINOGLYCOSIDEPEDS



[RETURN TO MAIN PAGE](#)

Please see our Benioff Children's Hospital [Cystic Fibrosis Guidelines](#) for further details.



## Determine the initial dose.

Prior to choosing a dosing regimen the clinical pharmacist should review the patient's previous aminoglycoside regimen(s) to determine if information from previous courses of therapy can aid in selecting dosing for a new course of treatment.

|                   | Dose   | Dose Adjustment  |
|-------------------|--|--|
| <b>Amikacin</b>   | Cystic Fibrosis (CF):<br>30 mg/kg/dose IV every 24 hours<br><br>Nontuberculosis Mycobacteria (NTM):<br>20 mg/kg/dose IV every 24 hours | Adjust for CrCl < 50 ml/min/1.73m <sup>2</sup> *<br><br>*Consider ASP/ID pharmacist consult for dose adjustment/level assessment |
| <b>Tobramycin</b> | 10 mg/kg/dose IV every 24 hours (max 15 mg/kg/dose)  |  |



## Determine therapeutic drug monitoring goals

| CF & NTM - Extended Interval Dosing |                          |                        |                          |
|-------------------------------------|--------------------------|------------------------|--------------------------|
| Tobramycin                          |                          | Amikacin               |                          |
| Goal Extrapolated Peak              | Goal Extrapolated Trough | Goal Extrapolated Peak | Goal Extrapolated Trough |
| 20 to 35 mcg/mL                     | < 1 mcg/mL               | 35 to 45 mcg/mL        | < 5 mcg/mL               |



[RETURN TO MAIN PAGE](#)



## Obtain post dose serum concentrations

With extended interval dosing, after the **first dose** if possible. No need to wait for steady-state as drug concentrations essentially go to 0 mcg/mL in between doses and drug is not expected to accumulate.

| Renal Function  | When to obtain level  | After which dose? |
|---|---|-------------------|
| CrCl > 50 or CRRT   | Post dose levels 2 and 6 hours after end of infusion                              | 1st dose          |
| CrCl < 50   | Post dose levels 2 and 12 hours after end of infusion                             | 1st dose          |
| Intermittent hemodialysis (iHD), peritoneal dialysis (PD) | Level obtained prior to the hemodialysis treatment is recommended to guide dosing | 1st dose          |



## Dose Adjustments

Use Bayesian software to estimate extrapolated peak and trough concentrations. Apply Bayesian modeling to evaluate the current regimen and adjust therapy as clinically indicated.

For step-by-step instructions on how to perform Bayesian modeling, please refer to the [Aminoglycoside PrecisePK Job Aid](#).



## Continued Monitoring

- For stable regimens, obtain a trough once weekly to confirm clearance.
- Consider two post-dose levels for extrapolated peak/trough analysis about once monthly, or less frequently if the patient remains stable.
- Increase monitoring if doses, clinical status, renal function, or toxicity risk change.



## Documentation

Please write a pharmacokinetic progress note in the patient's chart regardless of whether a dose adjustment was required or not.

Dotphrase = .RXAMINOGLYCOSIDEPEDS



# References

1. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomized controlled trial. *Lancet*. 2005 Feb 12-18;365(9459):573-8.
2. Smyth AR, Bhatt J. Once---daily versus multiple---daily dosing with intravenous aminoglycosides for cystic fibrosis. *Cochrane Database Syst Rev*. 2012 Feb 15;2:CD002009.
3. Whitehead A, Conway SP, Etherington C, et al. Once---daily tobramycin in the treatment of adult patients with cystic fibrosis. *Eur Respir J*. 2002 Feb;19(2):303---9.
5. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Resp Crit Care Med*. 2009 Nov 1;180(9):802---8.
6. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. *Antimicrob Agents Chemother*. 1999 Jul;43(7):1549---55.
7. Chmiele JF, Akshamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant *Staphylococcus aureus*, gram-negative bacteria, and multiple infections. *Ann Am Thorac Soc*. 2014 Sep;11(7):1120-9. doi: 10.1513/AnnalsATS.201402-050AS. PMID: 25102221; PMCID: PMC5467101.



# CONTRIBUTORS

Emilie Chebat  
Steve Grapentine  
Cynthia Huwe  
Ilexa Nicolau  
Sylvia Stofella  
Allyson Thrall

## Questions?

*[peds.asp@ucsf.edu](mailto:peds.asp@ucsf.edu)*